- Patent Title: Purine derivatives as CD73 inhibitors for the treatment of cancer
-
Application No.: US15306197Application Date: 2015-04-23
-
Publication No.: US10654884B2Publication Date: 2020-05-19
- Inventor: Salvacion Cacatian , David A. Claremon , Lanqi Jia , Angel Morales-Ramos , Suresh B. Singh , Shankar Venkatraman , Zhenrong Xu , Yajun Zheng
- Applicant: Vitae Pharmaceuticals, Inc.
- Applicant Address: DE Ingelheim am Rhein
- Assignee: Boehringer Ingelheim International GmbH
- Current Assignee: Boehringer Ingelheim International GmbH
- Current Assignee Address: DE Ingelheim am Rhein
- Agent Atabak R. Royaee
- International Application: PCT/US2015/027235 WO 20150423
- International Announcement: WO2015/164573 WO 20151029
- Main IPC: C07H19/16
- IPC: C07H19/16 ; C07H19/06 ; C07D473/36 ; C07D473/40 ; C07D405/04 ; C07D473/34 ; A61K31/517 ; A61K31/675 ; A61K31/7056 ; A61K31/7072 ; A61K31/7076 ; A61K45/06 ; C07D239/72 ; C07F9/6512 ; C07F9/6561 ; C07H19/052
Abstract:
Provided are novel purine nucleoside/nucleotide analogues compounds, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are inhibitors of CD73 and are useful in the treatment of cancer.
Public/Granted literature
- US20170044203A1 PURINE DERIVATIVES AS CD73 INHIBITORS FOR THE TREATMENT OF CANCER Public/Granted day:2017-02-16
Information query
IPC分类:
